The week of 2025-11-24, 20 holders filed a new Schedule 13D and 35 a new Schedule 13G reporting 5% or more of a company, and 0 13D filings stated in Item 4 an intent to influence the company. Open a company for every holder and the purpose each 13D states, quoted.
New Schedule 13D
| Filed | Company | Holder | Percent | Filing |
|---|---|---|---|---|
| 2025-11-25 | Cn Energy Group. Inc. | Yefang Zhang | 100% | SCHEDULE 13D |
| 2025-11-26 | Central Bancompany, Inc. | Central Bancompany, Inc. Amended & Restated Voting Trust Agreement, dated March 5, 2025 | 65.79% | SCHEDULE 13D |
| 2025-11-28 | Titan Mining Corporation | Augusta Ozama Investment LP | 54.6% | SCHEDULE 13D |
| 2025-11-28 | Gloo Holdings, Inc. | Grace and Mercy Foundation, Inc. | 27.5% | SCHEDULE 13D |
| 2025-11-25 | TCW Private Asset Income Fund | Apollo Principal Holdings B GP, LLC | 23.6% | SCHEDULE 13D |
| 2025-11-24 | Select Medical Holdings Corporation | Ortenzio Robert A | 11.3% | SCHEDULE 13D |
| 2025-11-25 | Super Hi International Holding Ltd. | Ping Shu | 11% | SCHEDULE 13D |
| 2025-11-24 | Verrica Pharmaceuticals Inc. | Caligan Partners LP | 9.99% | SCHEDULE 13D |
| 2025-11-26 | ENDRA Life Sciences Inc. | Anthony DiGiandomenico | 9.99% | SCHEDULE 13D |
| 2025-11-28 | Nabors Energy Transition Corp. II | ATG Fund II LLC | 9.97% | SCHEDULE 13D |
| 2025-11-25 | Epsilon Energy Ltd. | Yorktown Energy Partners XI, L.P. | 9.57% | SCHEDULE 13D |
| 2025-11-24 | Eightco Holdings Inc. | World Assets, Ltd. | 9.06% | SCHEDULE 13D |
| 2025-11-25 | Epsilon Energy Ltd. | Yorktown Energy Partners X, L.P. | 8.86% | SCHEDULE 13D |
| 2025-11-26 | Ventyx Biosciences, Inc. | Raju Mohan | 6% | SCHEDULE 13D |
| 2025-11-28 | Ainos, Inc. | Chun-Jung Tsai | 6% | SCHEDULE 13D |
| 2025-11-24 | Mega Matrix Inc | Yaman Demir | 5.94% | SCHEDULE 13D |
| 2025-11-26 | Newton Golf Company, Inc. | Brett Widney Hoge | 5.7% | SCHEDULE 13D |
| 2025-11-24 | Beazer Homes Usa Inc | Allan P. Merrill | 5.3% | SCHEDULE 13D |
| 2025-11-24 | Latigo Biotherapeutics, Inc. | Samsara BioCapital, L.P. | 5.3% | SCHEDULE 13D |
| 2025-11-26 | CEA Industries Inc. | YZILabs Management Ltd. | 5% | SCHEDULE 13D |
New Schedule 13G
| Filed | Company | Holder | Percent | Filing |
|---|---|---|---|---|
| 2025-11-24 | Evolution Global Acquisition Corp | Evolution Sponsor Holdings LLC | 25% | SCHEDULE 13G |
| 2025-11-26 | VisionWave Holdings, Inc. | GBT Technologies Inc. | 14.16% | SCHEDULE 13G |
| 2025-11-28 | Crescent Private Credit Income Corp. | BlueArc Capital Management, LLC | 12.5% | SCHEDULE 13G |
| 2025-11-28 | Knorex Ltd. | Raffles Venture (Direct) Pte. Ltd | 12% | SCHEDULE 13G |
| 2025-11-26 | CASI Pharmaceuticals, Inc. | Chen Zhenfeng | 11% | SCHEDULE 13G |
| 2025-11-25 | Borr Drilling Ltd | Azvalor Asset Management Sgiic Sa | 10% | SCHEDULE 13G |
| 2025-11-24 | SenesTech, Inc. | Glenbrook Capital Management | 9.99% | SCHEDULE 13G |
| 2025-11-28 | Clearmind Medicine Inc. | Nissim Daniel | 9.99% | SCHEDULE 13G |
| 2025-11-26 | Freight Technologies, Inc. | Fetch Compute Inc | 9.9% | SCHEDULE 13G |
| 2025-11-28 | Digital Currency X Technology Inc. | Orca Capital AG | 9.9% | SCHEDULE 13G |
| 2025-11-26 | Foxx Development Holdings Inc. | Alta Partners LLC | 9.8% | SCHEDULE 13G |
| 2025-11-24 | Heartflow, Inc. | HealthCor Partners Management LP | 7.9% | SCHEDULE 13G |
| 2025-11-25 | Invivyd, Inc. | Perceptive Advisors LLC | 7.9% | SCHEDULE 13G |
| 2025-11-28 | Vista Credit Strategic Lending Corp. | Citibank Korea Inc. as trustee of Samsung Vista Credit BDC Private Investment No. 1 | 7.6% | SCHEDULE 13G |
| 2025-11-25 | ConnectM Technology Solutions, Inc. | Arumilli LLC | 7.2% | SCHEDULE 13G |
| 2025-11-25 | Hall Chadwick Acquisition Corp | Saba Capital Management, L.P. | 6.67% | SCHEDULE 13G |
| 2025-11-26 | New ERA Energy & Digital, Inc. | Zhou Zachary Yi | 6.5% | SCHEDULE 13G |
| 2025-11-24 | Neuronetics, Inc. | Chernett Jorey | 6.4% | SCHEDULE 13G |
| 2025-11-24 | Spruce Biosciences, Inc. | Boone Peter David Mr | 6.4% | SCHEDULE 13G |
| 2025-11-26 | VisionWave Holdings, Inc. | GBT Tokenize Corp | 6.29% | SCHEDULE 13G |
| 2025-11-26 | FAT Brands, Inc. | Muhammad Asif Seemab | 6.2% | SCHEDULE 13G |
| 2025-11-26 | Figma, Inc. | Wu-Wallace Family Trust | 6% | SCHEDULE 13G |
| 2025-11-24 | Eledon Pharmaceuticals Inc | Matthew D. Perry | 5.98% | SCHEDULE 13G |
| 2025-11-26 | Crown Reserve Acquisition Corp. I | Feis Equities LLC | 5.87% | SCHEDULE 13G |
| 2025-11-28 | OnKure Therapeutics, Inc. | Prosight Management, LP | 5.8% | SCHEDULE 13G |
| 2025-11-28 | Knorex Ltd. | Ritz Venture Capital Pte Ltd | 5.7% | SCHEDULE 13G |
| 2025-11-24 | GRAIL, Inc. | Dapice Joshua J. | 5.5% | SCHEDULE 13G |
| 2025-11-24 | Mersana Therapeutics, Inc. | 683 Capital Management, LLC | 5.47% | SCHEDULE 13G |
| 2025-11-24 | Sylvamo Corp | Integrated Core Strategies (US) LLC | 5.4% | SCHEDULE 13G |
| 2025-11-26 | Heron Therapeutics, Inc. | Clearline Capital LP | 5.3% | SCHEDULE 13G |
| 2025-11-24 | XPEL, Inc. | Alta Fox Capital Management, LLC | 5.2% | SCHEDULE 13G |
| 2025-11-26 | Range Capital Acquisition Corp II | Linden Advisors LP | 5.1% | SCHEDULE 13G |
| 2025-11-26 | Jushi Holdings Inc. | Marex Securities Products Inc. | 5.1% | SCHEDULE 13G |
| 2025-11-24 | BILL Holdings, Inc. | Point72 Asset Management, L.P. | 5% | SCHEDULE 13G |
| 2025-11-25 | Entrada Therapeutics, Inc. | TCG Crossover GP I, LLC | 5% | SCHEDULE 13G |
Stated intent
No 13D this week stated an intent to influence the company.
Tools for this story
Each opens in a new tab. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.